Tommie Floyd
Family · Douglasville, GANPI 1013396878
Payments from drug & device makers
Across 74 payments — averaging $22.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$265
- Bayer$231
- Lilly USA, LLC$220
- Novo Nordisk$177
- Abbott$175
- Amgen$104
- plus $473 from 15 others
What the payments were for
- Food & beverage$1,645100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $265 |
| Bayer | 7 | $231 |
| Lilly USA, LLC | 11 | $220 |
| Novo Nordisk | 6 | $177 |
| Abbott | 4 | $175 |
| Amgen | 7 | $104 |
| Sanofi-aventis U.S. LLC | 4 | $90 |
| Idorsia Pharmaceuticals US Inc | 4 | $68 |
| Pfizer | 3 | $51 |
| Daiichi Sankyo Inc. | 2 | $43 |
| Dexcom, Inc. | 2 | $38 |
| Boehringer Ingelheim | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| AbbVie | 1 | $21 |
| Exact Sciences | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| GSK | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,645 in reported general payments places this provider in the 75th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $72,304 |
| Lactulose | 22 | $48,514 |
| MounjaroTirzepatide | 21 | $27,802 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $10,007 |
| Metformin Hcl | 137 | $9,394 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $7,170 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 82 | $2,088 |
| Esomeprazole Magnesium | 19 | $1,872 |
| Triamcinolone Acetonide | 36 | $1,766 |
| Ezetimibe | 28 | $1,489 |
| PaxlovidNirmatrelvir/Ritonavir | 13 | $1,429 |
| Atorvastatin Calcium | 206 | $1,327 |
| Fenofibrate | 39 | $1,152 |
| Gabapentin | 72 | $1,088 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,063 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $177 | $72,30468 claims |
| Lilly USA, LLCMounjaro | $220 | $27,80221 claims |
| GSKTrelegy Ellipta | $16 | $10,00714 claims |
| PfizerPaxlovid | $51 | $1,42913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,258 family providers in Georgia.
Other family in Douglasville
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.